- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Extensive-stage small cell lung cancer (ES-SCLC)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Tarlatamab – March 2026
Powder for injection 1 mg, Powder for injection 10 mg
Last updated
11 March 2026